MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Foslevodopa/foscarbidopa subcutaneous infusion shows similar infusion site reaction severity score across range of infusion rates in patients with Parkinson’s disease

    L. Schlachter, S. Stodtmann, S. Talapala, M. Facheris, M. Rosebraugh (Ludwigshafen, Germany)

    Objective: Characterize the relationship between foslevodopa/foscarbidopa infusion rate and infusion site reaction (ISR) score in patients with Parkinson’s disease (PD) Background: As PD progresses, motor…
  • 2023 International Congress

    Neuromelanin related 7T MRI of the locus coeruleus differs between Parkinson’s disease and controls

    A. Wolters, M. Heijmans, N. Priovoulos, H. Jacobs, A. Postma, Y. Temel, M. Kuijf, S. Michielse (Maastricht, Netherlands)

    Objective: To compare the signal intensity of the substantia nigra and locus coeruleus on Magnetization Transfer 7T MRI between PD patients and healthy controls (HC)…
  • 2023 International Congress

    IP-RT-QuIC Identify Disease-Specific Alpha-Synuclein Seeds in serum from patients with syncleinopathy

    A. Okuzumi, T. Hatano, G. Matsumoto, N. Hattori (Tokyo, Japan)

    Objective: To examine whether alpha-synuclein (aSyn) seed exists in the serum and its potential as a serum biomarker. Background: Parkinson’s disease (PD) and Multiple system…
  • 2023 International Congress

    The effect of cathodal transcranial direct current stimulation in the treatment of Levodopa-Induced Dyskinesias in Parkinson’s Disease: a preliminary report.

    B. Angeloni, R. Di Iorio, F. Bove, P. Sanginario, C. Piano, A R. Bentivoglio, P. Calabresi (Rome, Italy)

    Objective: Our study aims to demonstrate the possible effect of transcranial direct current stimulation (tDCS) in the treatment of Levodopa-induced dyskinesias (LIDs) in patients with…
  • 2023 International Congress

    Does sex affect worsening of cognitive and IADL functions in PD with and without PD-MCI?

    I. Liepelt-Scarfone, M. Bode, S. Solbrig, K. Brockmann, W. Maetzler, I. Wurster, M. Timmers, D. Berg, S. Becker (Tübingen, Germany)

    Objective: To define how sex affects worsening of cognition and instrumental activities of daily living (IADLs) in a heterogeneous cohort of people with Parkinson’s disease…
  • 2023 International Congress

    Impact of deep brain stimulation of the subthalamic nuclei on non-motor symptoms in Parkinson’s disease: a monocentric prospective study with a 12-month follow-up

    V. Leclercq, V. Donckels, E. Hanon, S. Dethy (Sint-Pieters-Leeuw, Belgium)

    Objective: The aim of the study is to evaluate the evolution of non-motor symptoms in Parkinson's disease (PD) in patients treated with deep brain stimulation…
  • 2023 International Congress

    Multicenter, randomized, placebo-controlled, double-blind, parallel-group proof-of-concept study of lixisenatide in patients with early Parkinson’s disease (PD): the LIXIPARK trial (NCT03439943)

    WG. Meissner, P. Remy, C. Giordana, D. Maltete, P. Damier, JL. Houeto, C. Geny, L. Hopes, F. Durif, G. Defer, C. Tranchant, JC. Corvol, N. Carriere, JP. Azulay, S. Drapier, P. Krystkowiak, C. Thalamas, A. Benard, O. Rascol, N. Ns-Park/fcrin (Bordeaux, France)

    Objective: To evaluate the “disease-modifying” effect of lixisenatide as adjunct to antiparkinsonian medications in patients with early PD. Background: Lixisenatide, a glucagon-like peptide 1 receptor…
  • 2023 International Congress

    The feasibility and efficacy of speech therapy via video call in patients with Parkinson’s disease: a preliminary study

    HJ. Chang, J. Kim, KA. Woo, JY. Joo, S. Kim, S. Lee, B. Jin, HY. Jeon, B. Jeon, HJ. Kim (Daejeon, Republic of Korea)

    Objective: To evaluate the feasibility and efficacy of video call-based speech therapy for patients with Parkinson’s disease (PD) with speech problems. Background: PD patients commonly…
  • 2023 International Congress

    The natural history of Parkinson’s disease in LRRK2 G2019S carriers

    M. Kmiecik, D. Coker, K. Heilbron, S. Aslibekyan, J. Shelton, P. Cannon, L. Norcliffe-Kaufmann (Sunnyvale, USA)

    Objective: To document differences between the evolution of self-reported symptoms and prodromal markers in LRRK2 G2019S carriers and non-carriers with and without Parkinson’s Disease (PD).…
  • 2023 International Congress

    Management of Sigmoid Volvulus in Parkinson’s patients presenting to Royal Berkshire Hospital, Reading ,UK.

    M. Khwaja, S. Alam, A. Chatterjee, E. Castaneda-Cicedo (Reading, United Kingdom)

    Objective: To evaluate acute management of volvulus in Parkinson’s Background: Constipation affects upto 50% of patients with Parkinson's and sigmoid volvulus is an under recognized…
  • « Previous Page
  • 1
  • …
  • 99
  • 100
  • 101
  • 102
  • 103
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley